EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinie

Buprenorphine for Cancer Pain: Evidence, Guidelines, and Clinical Rationale for Early Use

Marcin Chwistek, Leigh Kinczewski, Sorin Buga, Julia L Agne, Natalie Moryl, Enas Kandil, Mona Gupta, Magdalena Anitescu, Saba Javed, Michael Noonan, Dylan Sherry

Journal of the National Comprehensive Cancer Network · 2026-06 · 24 (6)

DOI: 10.6004/jnccn.2025.7132 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-06. Verfasst von Marcin Chwistek und 10 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Hematology and Oncology, Fox Chase Cancer Center/Temple University Health, Philadelphia, PA. Hauptthemen laut MEDLINE: Buprenorphine, Cancer Pain, Analgesics, Opioid, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 242 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As cancer survivorship increases, long-term opioid therapy (LTOT) has become more common in oncology, raising concerns about opioid-related harms. Buprenorphine offers unique pharmacologic advantages that position it as a safer alternative to full agonist opioids (FAOs), yet it remains underutilized in the management of cancer pain (CP). This article reviews the clinical rationale, supporting evidence, and practical considerations for using buprenorphine in managing CP throughout the cancer care continuum, with guidance from the NCCN Adult Cancer Pain Guideline Panel. This review synthesizes findings from pharmacologic research, clinical trials, guideline updates, and expert consensus. It examines the pharmacodynamics, dosing strategies, and safety of buprenorphine in vulnerable populations, as well as its potential to mitigate opioid-related complications. This review also discusses implementation barriers, including prescriber hesitancy, formulary restrictions, and stigma. Buprenorphine provides analgesia comparable to FAOs while reducing the risks of respiratory depression, opioid-induced hyperalgesia, hormonal disruption, and neurocognitive impairment. Buprenorphine may help reduce the neuroadaptive changes associated with LTOT, thereby preserving analgesic efficacy and improving long-term functional outcomes. Multiple formulations and flexible dosing options support personalized care, although regulatory restrictions and clinician unfamiliarity remain significant barriers. Buprenorphine is a viable yet underutilized option for managing CP, particularly when LTOT is anticipated. Broader clinical integration will require more precise guideline recommendations, clinician education, and policy reform. A paradigm shift toward early and proactive buprenorphine use could significantly improve safety, function, and quality of life in oncology patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineCancer PainAnalgesics, OpioidNeoplasmsHumansPractice Guidelines as TopicPain Management

Substanzen

BuprenorphineAnalgesics, Opioid

Autor:innen und Institutionen

  • 1Department of Hematology and Oncology, Fox Chase Cancer Center/Temple University Health, Philadelphia, PA.
  • 2Department of Supportive Care Medicine, City of Hope, Duarte, CA.
  • 3Division of Palliative Medicine, The Ohio State University Wexner Medical Center, Columbus, OH.
  • 4Memorial Sloan Kettering Cancer Center/Weill Cornell Medicine, New York, NY.
  • 5Department of Anesthesiology, University of Texas Southwestern Medical Center, Dallas, TX.
  • 6University Hospitals Seidman Cancer Center/Case Western Reserve University, Cleveland, OH.

Zitieren

APA

Chwistek, M., Kinczewski, L., Buga, S., Agne, J. L., Moryl, N., Kandil, E., Gupta, M., Anitescu, M., Javed, S., Noonan, M., & Sherry, D. (2026). Buprenorphine for Cancer Pain: Evidence, Guidelines, and Clinical Rationale for Early Use. Journal of the National Comprehensive Cancer Network, 24(6). https://doi.org/10.6004/jnccn.2025.7132

Vancouver

Chwistek M, Kinczewski L, Buga S, Agne JL, Moryl N, Kandil E, et al. Buprenorphine for Cancer Pain: Evidence, Guidelines, and Clinical Rationale for Early Use. Journal of the National Comprehensive Cancer Network. 2026;24(6). doi:10.6004/jnccn.2025.7132

BibTeX
@article{Chwistek2026,
  author = {Chwistek, Marcin and Kinczewski, Leigh and Buga, Sorin and Agne, Julia L and Moryl, Natalie and Kandil, Enas and Gupta, Mona and Anitescu, Magdalena and Javed, Saba and Noonan, Michael and Sherry, Dylan},
  title = {Buprenorphine for Cancer Pain: Evidence, Guidelines, and Clinical Rationale for Early Use},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  volume = {24},
  number = {6},
  doi = {10.6004/jnccn.2025.7132}
}
Kostenlos starten →